<DOC>
	<DOCNO>NCT02596724</DOCNO>
	<brief_summary>Prospective observational registry link result genomic molecular test treatment response survival measure patient diagnose breast cancer target neo-adjuvant therapy . Analysis include test impact treatment decision outcome .</brief_summary>
	<brief_title>TME Neoadjuvant Breast Registry</brief_title>
	<detailed_description>Physicians order test patient part standard care ; report whether test result influence : selection standard therapy clinical trial ; offer insight mid therapy treatment change ; help physician determine therapy offer patient complete pathologic response . Patient demographic , diagnosis , type treatment , surgery pathologic result record . Patients follow 5 year . Recurrence survival data record . Participating site submit de-identified patient data via electronic case report form ( eCRFs ) secure study website . All patient require sign Informed Consent Form . All investigator staff Human Subject Protection Training .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Patients histologically proven invasive breast cancer start schedule start neoadjuvant chemotherapy endocrine therapy Ages 1890 Written inform consent Patients excisional biopsy axillary dissection Patients confirm metastatic disease Patients recent chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Neoadjuvant therapy breast cancer</keyword>
</DOC>